Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Grupo Biotoscana
Private Company Edition: Westlake Village BioPartners-founded Neuron23 will take the LRRK2 inhibitor NEU-723 for Parkinson’s disease into human testing before the end of 2022. Also, Celsius raised $83m in fresh VC cash and ITM added another €33m to its recent €25m equity financing.
Agios’ cellular metabolism expertise first delivered cancer drugs but sees greater opportunity in genetically defined diseases. CEO Jackie Fouse talked to Scrip about the business strategy.
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Biotoscana Farma S.A.
- Biotoscana Investments SA
- Biotoscana International